Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

Study Evaluating PD-0299685 for the Treatment of Vasomotor Symptoms (Hot Flashes / Flushes) Associated With Menopause

ClinicalTrials.gov ID: NCT00314964

Public ClinicalTrials.gov record NCT00314964. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 3:49 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study Evaluating PD-0299685 for Treatment of Vasomotor Symptoms Associated With Menopause

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The primary purpose of this study is to determine if PD-0299685 is effective and safe in the treatment of vasomotor symptoms (hot flashes / flushes) associated with menopause.

Study identification

NCT ID
NCT00314964
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Pfizer
Industry
Enrollment
527 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range
40 Years to 70 Years
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 31, 2006
Primary completion
Not listed
Completion
Jun 30, 2007
Last update posted
Mar 15, 2011

2006 – 2007

United States locations

U.S. sites
56
U.S. states
24
U.S. cities
44
Facility City State ZIP Site status
Pfizer Investigational Site Phoenix Arizona 85015
Pfizer Investigational Site Phoenix Arizona 85032
Pfizer Investigational Site Tucson Arizona 85704
Pfizer Investigational Site Tucson Arizona 85741
Pfizer Investigational Site Jonesboro Arkansas 72401
Pfizer Investigational Site Greenbrae California 94904
Pfizer Investigational Site San Diego California 92103
Pfizer Investigational Site San Diego California 92128
Pfizer Investigational Site New London Connecticut 06320
Pfizer Investigational Site Leesburg Florida 34748
Pfizer Investigational Site Longwood Florida 32779
Pfizer Investigational Site Tampa Florida 33606
Pfizer Investigational Site Tampa Florida 33614
Pfizer Investigational Site West Palm Beach Florida 33407
Pfizer Investigational Site Alanta Georgia 30342
Pfizer Investigational Site Alpharetta Georgia 30005
Pfizer Investigational Site Atlanta Georgia 30342
Pfizer Investigational Site Decatur Georgia 30034
Pfizer Investigational Site Stockbridge Georgia 30281
Pfizer Investigational Site Chicago Illinois 60610
Pfizer Investigational Site Indianapolis Indiana 46202
Pfizer Investigational Site Indianapolis Indiana 46227
Pfizer Investigational Site Indianapolis Indiana 46280
Pfizer Investigational Site Baltimore Maryland 21211
Pfizer Investigational Site North Dartmouth Massachusetts 02747
Pfizer Investigational Site Chaska Minnesota 55318
Pfizer Investigational Site Waconia Minnesota 55387
Pfizer Investigational Site Olive Branch Mississippi 38654
Pfizer Investigational Site Springfeild Missouri 65807
Pfizer Investigational Site Springfeild Missouri 65810
Pfizer Investigational Site Lincoln Nebraska 68510
Pfizer Investigational Site Omaha Nebraska 68131
Pfizer Investigational Site Lebanon New Hampshire 03756
Pfizer Investigational Site Lawrenceville New Jersey 08648
Pfizer Investigational Site New Brunswick New Jersey 08901
Pfizer Investigational Site New Bern North Carolina 28562
Pfizer Investigational Site Raleigh North Carolina 27609
Pfizer Investigational Site Winston-Salem North Carolina 27103
Pfizer Investigational Site Cincinnati Ohio 45219
Pfizer Investigational Site Cleveland Ohio 44122
Pfizer Investigational Site Columbus Ohio 43213
Pfizer Investigational Site Sellersville Pennsylvania 18960
Pfizer Investigational Site Columbia South Carolina 29201
Pfizer Investigational Site Austin Texas 78705
Pfizer Investigational Site San Antonio Texas 78212
Pfizer Investigational Site San Antonio Texas 78229
Pfizer Investigational Site San Antonio Texas 78258
Pfizer Investigational Site Salt Lake City Utah 84109
Pfizer Investigational Site Salt Lake City Utah 84121
Pfizer Investigational Site Arlington Virginia 22205
Pfizer Investigational Site Richmond Virginia 23226
Pfizer Investigational Site Richmond Virginia 23229
Pfizer Investigational Site Richmond Virginia 23294
Pfizer Investigational Site Virginia Beach Virginia 23455
Pfizer Investigational Site Seattle Washington 98105
Pfizer Investigational Site Spokane Washington 99207

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 24 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00314964, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 15, 2011 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00314964 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →